Science in art
Recent articles
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.